SMARCA2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
SMARCA2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy was generated using PatSnap Life Sciences MCP Servers. Target & Disease MCP contributed the biology and disease context, while Clinical Trials MCP contributed validation evidence and clinical competition signals.
Why this report exists: it shows how AI agents can use PatSnap MCP data to produce target evaluation workflows covering biology, validation, competition, IP, and R&D recommendation. Explore PatSnap Life Sciences MCP Servers for AI agents.
Executive Summary
This SMARCA2 Target Evaluation Report is generated from PatSnap MCP data. SMARCA2 is an emerging synthetic-lethality and degrader target for SMARCA4-mutant cancers, including NSCLC, but clinical evidence remains early and several programs have already terminated.
Target
SMARCA2
UniProt P51531
Drug Count
75
68 development-stage assets
Trials
5
SMARCA2 NSCLC trials retrieved by Clinical Trials MCP
Results
0
Clinical Trials MCP result records
Target Attractiveness Snapshot
Biology
Target & Disease MCP describes SMARCA2 as an ATPase component of SWI/SNF chromatin remodeling complexes that alters DNA-nucleosome topology and regulates transcription.
Disease Context
The clinical strategy targets SMARCA4-mutant or SMARCA4-deficient tumors that may depend on SMARCA2 function.
Strategy
Position SMARCA2 as an early synthetic-lethality target requiring tight biomarker selection and degrader quality.
Overall Target Evaluation Score: 70/100
- Biology: Synthetic-lethality rationale is strong in SMARCA4-loss contexts.
- Clinical validation: Clinical Trials MCP returned 5 NSCLC trials and no released result records.
- Competition: Competition is emerging but unstable, with terminated degrader programs.
- White space: White space remains in oral degraders, SMARCA4 diagnostics and tolerability.
Biology and Disease Rationale
SMARCA2 is an ATP-dependent chromatin-remodeling ATPase in SWI/SNF complexes. Target & Disease MCP links it to transcriptional activation and repression, DNA-histone contact remodeling, and BAF complex biology.
Clinical Trials MCP returned PLX-61639, LY4050784, PRT3789, PRT7732 and PRT3789 plus pembrolizumab/docetaxel strategies in advanced or metastatic solid tumors with SMARCA4 mutation. However, result search returned zero released NSCLC records for SMARCA2.
Explore PatSnap Life Sciences MCP Servers for AI agents
Validation and Clinical Competition
| Emerging degrader class | PRT7732 is an oral SMARCA2 degrader study in SMARCA4-mutant solid tumors. |
| Combination exploration | PRT3789 was studied with pembrolizumab in advanced or metastatic SMARCA4-mutant tumors. |
| Pipeline continuation | PLX-61639 and LY4050784 are recruiting Phase 1 programs. |
| Readout gap | Clinical Trials MCP returned no released result records for SMARCA2 in NSCLC. |
IP and Competitive Strategy
SMARCA2 IP should cover degrader binders, ternary complex design, SMARCA4-loss diagnostics, transcriptional response biomarkers, oral exposure, and claims for SMARCA4-mutant NSCLC.
Recommendation
SMARCA2 is a good emerging SEO and R&D target, but the evidence is early. Advance only with validated SMARCA4-loss selection and a degrader profile that can avoid class execution failures.
Bottom line: This SMARCA2 Target Evaluation Report is generated from PatSnap MCP data. SMARCA2 is an emerging synthetic-lethality and degrader target for SMARCA4-mutant cancers, including NSCLC, but clinical evidence remains early and several programs have already terminated.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
